Takeda R, Yamazaki T, Ito Y, Koshida H, Morise T, Miyamori I, Hashimoto T, Morimoto S
Second Department of Internal Medicine, Kanazawa University, Japan.
Acta Endocrinol (Copenh). 1992 Feb;126(2):186-90. doi: 10.1530/acta.0.1260186.
A case of primary aldosteronism treated with spironolactone therapy has been followed up for 24 years. This is probably the longest case of spironolactone therapy for primary aldosteronism that has ever been reported. Long-term treatment with spironolactone controlled the hypertension and prevented hypokalemic alkalosis in this patient, without any deleterious effects on steroid biosynthesis. Based on data obtained during dose reduction and subsequent withdrawal of spironolactone, it is suggested that the suppressed plasma renin activity associated with adenoma-induced aldosteronism develops prior to hypokalemia and hypertension.
一例接受螺内酯治疗的原发性醛固酮增多症患者已随访24年。这可能是有报道以来接受螺内酯治疗原发性醛固酮增多症时间最长的病例。长期使用螺内酯治疗控制了该患者的高血压并预防了低钾性碱中毒，且对类固醇生物合成无任何有害影响。根据在减少螺内酯剂量及随后停药期间获得的数据，提示与腺瘤性醛固酮增多症相关的血浆肾素活性受抑制在低钾血症和高血压之前就已出现。
